Clinical trial
Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot…
NCT00003744 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003744 |
|---|---|
| Title | Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery |
| Official title | Gemcitabine for Advanced Salivary Cancer: A Phase II Study |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine |
| Enrollment | 16 |
| Start date | Nov 1, 1998 |
| Primary completion | May 1, 2004 |
| Completion | May 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 19, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: